Good Manufacturing Practices

All Little Green Pharma’s medicinal cannabis products are manufactured in accordance with applicable GMP guidelines. In Australia our facilities are audited and licensed by the Therapeutic Goods Administration (TGA). Our Manufacturing Partner’s GMP licensing is recognised by EU regulatory authorities as meeting EU-GMP standards, enabling LGP to import and sell medicinal cannabis products into the EU. Our Manufacturing Partner is licensed to produce oil, gel cap, suppository, emulsion, spray products, and dried cannabis flower. Little Green Pharma holds a Therapeutic Goods Administration (TGA) Good Manufacturing Practices (GMP) licence for its manufacturing facility in Western Australia.

The GMP licencing of the Company’s manufacturing facility is the culmination of a two-year regulatory strategy. Little Green Pharma now holds over 20 State and Federal operating authorisations, allowing it to operate a fully in-house and vertically-integrated cannabis cultivation, production, manufacturing, and wholesaling supply chain, capable of supplying various LGP branded medicinal cannabis products into Australian and international markets. The manufacturing facility was constructed with funding support from the West Australian Government and represents a regional manufacturing success story for South West Western Australia.

The Denmark Facility, which meets EU GACP cultivation standards and holds an EU recognised GMP manufacturing licence. The facilities location within EU avoids many EU export/ import barriers and requires substantially less export and logistics resourcing than sales from Australia into Europe. This also improves LGP’s EU distribution strategy by serving European customers from a European based facility.

Safety of Medicinal Cannabis and side effects

Medicinal cannabis has a favourable side effect profile compared to many other medications and is generally relatively well tolerated by patients. In addition, the risk of severe, adverse events or dependence is low with medicinal cannabis.1

1. Therapeutics Goods Administration, ‘Guidance for the use of medicinal cannabis in Australia, Overview’, Australian Government, Department of Health, Therapeutic Goods Administration, 2017, (accessed May 2022).

Return to Top